Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Neurosci Lett. 2010 Sep 6;481(2):88-91. doi: 10.1016/j.neulet.2010.06.058. Epub 2010 Jun 25.
Zonisamide, originally known as an antiepileptic drug, has been approved in Japan as adjunctive therapy with levodopa for the treatment of Parkinson's disease (PD). Although zonisamide reduces neurotoxicity, the precise mechanism of this action is not known. Here, we show that zonisamide increases cell viability in SH-SY5Y cells via an anti-apoptotic effect and by upregulating levels of manganese superoxide dismutase (MnSOD). These results would give us novel evidences of PD treatment.
唑尼沙胺最初是一种抗癫痫药物,在日本已被批准作为左旋多巴治疗帕金森病 (PD) 的辅助疗法。虽然唑尼沙胺可降低神经毒性,但这种作用的确切机制尚不清楚。在这里,我们通过抗凋亡作用和上调锰超氧化物歧化酶 (MnSOD) 的水平显示,唑尼沙胺可增加 SH-SY5Y 细胞的细胞活力。这些结果将为我们提供治疗 PD 的新证据。